A Guidebook on Emerging Treatment Strategies in CLL and the Pharmacist’s Role in Optimizing Therapy

This activity includes patient counseling video vignettes.

Program Description

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia, primarily affecting older adults. Historic treatment approaches have focused on prolonging survival and improving quality of life through the use of chemoimmunotherapy. BTK and BCL-2 inhibitors have impacted the management of CLL, and pharmacists are essential in optimizing clinical outcomes for this patient population. This activity will review clinical data for the use of BTK and BCL-2 inhibitors in CLL and will also focus on the rationale for combination therapies. Additionally, key counseling points will be enforced, including adverse effect management strategies and methods to improve coordination of care.

Target Audience: Health system pharmacists and oncology pharmacists
Type of Activity: Application
Release date: March 30, 2022
Expiration date: May 15, 2023

Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze safety and efficacy data for approved indications of small molecule inhibitors of BTK and BCL-2 in the treatment of chronic lymphocytic leukemia (CLL).
• Explain challenges and benefits associated with combination therapeutic strategies for CLL.
• Determine a monitoring and management plan for a patient receiving treatment with a BTKi and/or venetoclax to minimize toxicity.  
• Identify strategies to optimize care coordination for patients with CLL receiving combination therapy with a BTKi and/or venetoclax.

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 290-0000-22-131-H01-P.. The activity is available for CE credit through May 15, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Carmen N. Janes, PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Meg Taylor, PharmD, CPP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta

Medical Writer

Evelina Kolychev, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose:

Stock/Shareholder: Merck, Teva

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms